BroadOak Capital Partners has announced a series of new growth investments that expand its life sciences platform and reinforce its position as a long-term partner to emerging industry leaders. The activity includes the first investment from BroadOak Fund VI, a growth equity financing in Azure Biosystems, marking the third time in twenty years that BroadOak has partnered with the company’s founders.
Alongside the Fund VI investment in Azure Biosystems, BroadOak also formed and capitalized a special purpose vehicle to support Codis, previously known as Particle Dynamics, in completing its acquisition of EUROAPI’s Haverhill site. The firm further expanded its portfolio with new investments in VIDA Diagnostics and Prognos Health, deepening its presence across analytics, diagnostics, and data intelligence segments within the life sciences sector.
These investments reflect BroadOak’s continued strategy of supporting companies that enhance the way scientific research is conducted and how scientific breakthroughs reach the market. The firm’s recent expansion of its capital base has also strengthened its capacity to serve as a durable partner across market cycles. In October 2025, BroadOak added more than $200 million of permanent capital to its multi-vehicle investment platform, enabling greater flexibility in pursuing strategic opportunities and supporting the growth of its portfolio companies.
BroadOak Capital Partners continues to focus on direct investments and advisory services for companies in research tools, consumables, diagnostics, and biopharma services. With over 75 investments and more than 50 advised M&A transactions, the firm remains a significant contributor to innovation within the life sciences ecosystem.
KEY QUOTES:
“BroadOak’s partnership enables us to expand our platform’s reach and deliver even greater insights to life sciences organizations striving to improve patient outcomes.”
Sundeep Bhan, CEO of Prognos Health
“We are happy to report continued investment into the companies that are improving the way life sciences research is conducted and how the resulting breakthroughs are delivered to market.”
Bill Snider, Partner at BroadOak
